NZ709803A - Compositions comprising 15-ohepa and methods of using the same - Google Patents

Compositions comprising 15-ohepa and methods of using the same

Info

Publication number
NZ709803A
NZ709803A NZ709803A NZ70980314A NZ709803A NZ 709803 A NZ709803 A NZ 709803A NZ 709803 A NZ709803 A NZ 709803A NZ 70980314 A NZ70980314 A NZ 70980314A NZ 709803 A NZ709803 A NZ 709803A
Authority
NZ
New Zealand
Prior art keywords
ohepa
compositions
methods
same
fatty liver
Prior art date
Application number
NZ709803A
Other languages
English (en)
Inventor
Jonathan Rowe
Kevin Duffy
John Climax
Original Assignee
Afimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Afimmune Ltd filed Critical Afimmune Ltd
Publication of NZ709803A publication Critical patent/NZ709803A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
NZ709803A 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same NZ709803A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1301626.6A GB201301626D0 (en) 2013-01-30 2013-01-30 Composition comprising 15-OHEPA and methods of using the same
PCT/EP2014/051455 WO2014118097A1 (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Publications (1)

Publication Number Publication Date
NZ709803A true NZ709803A (en) 2020-05-29

Family

ID=47891001

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ709803A NZ709803A (en) 2013-01-30 2014-01-24 Compositions comprising 15-ohepa and methods of using the same

Country Status (27)

Country Link
US (6) US20150224076A1 (https=)
EP (2) EP2762143B1 (https=)
JP (2) JP6363104B2 (https=)
KR (6) KR20250105691A (https=)
CN (2) CN111214464A (https=)
AU (2) AU2014211628B2 (https=)
BR (1) BR112015018270A2 (https=)
CA (1) CA2897343C (https=)
CY (1) CY1117209T1 (https=)
DK (1) DK2762143T3 (https=)
ES (2) ES2759448T3 (https=)
GB (1) GB201301626D0 (https=)
HR (1) HRP20160203T1 (https=)
HU (1) HUE026901T2 (https=)
IL (3) IL239893A (https=)
MX (2) MX364646B (https=)
NZ (1) NZ709803A (https=)
PH (1) PH12015501582B1 (https=)
PL (1) PL2762143T3 (https=)
PT (1) PT2762143E (https=)
RS (1) RS54584B1 (https=)
RU (2) RU2671208C2 (https=)
SG (2) SG11201505457PA (https=)
SI (1) SI2762143T1 (https=)
SM (1) SMT201600069B (https=)
WO (1) WO2014118097A1 (https=)
ZA (2) ZA201505018B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
SG10202000496XA (en) * 2014-01-10 2020-03-30 Afimmune Ltd Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
MA41120A (fr) * 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
EP3247348A1 (en) * 2015-01-16 2017-11-29 Afimmune Limited Compositions comprising 15-hepe and methods of using the same
BR112017023164A2 (en) 2015-04-28 2018-07-24 Pronova Biopharma Norge As and method of preventing and / or treating non-alcoholic steatohepatitis in an individual in need thereof
CN117402059A (zh) * 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
KR20180094516A (ko) * 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법
HRP20241643T1 (hr) 2017-12-06 2025-02-14 Basf As Derivati masnih kiselina za liječenje nealkoholnog steatohepatitisa
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases
CN115215725A (zh) * 2021-04-15 2022-10-21 宋晓瑜 一种制备乙酸薰衣草酯及薰衣草醇的方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05186342A (ja) * 1992-01-10 1993-07-27 Fujirebio Inc 免疫調節作用を併せもつ抗炎症剤
AU683027B2 (en) 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
JPH09505562A (ja) 1993-10-01 1997-06-03 アール．ピー．シェーラー コーポレイション 香料を小分けして提供する方法および組成物
US20020055539A1 (en) * 1996-10-02 2002-05-09 Bockow Barry I. Compositions and methods for treating cardiovascular conditions
WO1999058120A1 (en) * 1998-05-08 1999-11-18 Rolf Berge USE OF NON-β-OXIDIZABLE FATTY ACID ANALOGUES FOR TREATMENT OF SYNDROME-X CONDITIONS
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
CN1250230C (zh) * 2001-09-30 2006-04-12 中国药品生物制品检定所 海狗油作为制备治脂肪肝药的应用
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
US20050239889A1 (en) 2004-04-26 2005-10-27 Jean Gosselin In vivo release of endogenous anti-microbial mediators by leukotriene B4 (LTB4) administration
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
EP1973536A2 (en) * 2006-01-05 2008-10-01 Reliant Pharmaceuticals, Inc. Treatment of fatty liver
BRPI0715402A2 (pt) 2006-08-08 2013-11-26 Lipomics Technologies Inc Marcadores de doença hepática gordurosa não alcoólica (nafld) e esteatohepatite não alcoólica (nash) e métodos de uso dos mesmos
WO2008126363A1 (ja) * 2007-03-30 2008-10-23 Kowa Company, Ltd. 脂肪肝又は非アルコール性脂肪性肝炎の予防及び／又は治療のための医薬
GB0802116D0 (en) 2008-02-05 2008-03-12 Natural Enviromental Res Counc Treatment
WO2009154230A1 (ja) * 2008-06-17 2009-12-23 持田製薬株式会社 非アルコール性脂肪肝炎の予防／改善・治療薬
EP2415748A4 (en) * 2009-02-20 2013-08-07 Univ Tokyo NEW INFLAMMATORY COMPOUNDS
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
JP5909183B2 (ja) * 2010-08-19 2016-04-26 国立大学法人 東京大学 オメガ３系脂肪酸由来の新規抗炎症性代謝物
US20130310422A1 (en) 2010-09-01 2013-11-21 The General Hospital Corporation Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
WO2012135032A2 (en) 2011-03-25 2012-10-04 The Brigham And Women's Hospital, Inc. Anti-inflammatory particles
US20120264824A1 (en) 2011-04-15 2012-10-18 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
UA114615C2 (uk) 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
DK2858496T3 (da) * 2012-05-10 2023-07-24 Solutex Na Llc Olier med anti-inflammatorisk aktivitet, som indeholder naturlige specialiserede pro-afhjælpningsmediatorer og deres forløbere
GB201213484D0 (en) * 2012-07-30 2012-09-12 Dignity Sciences Ltd Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
GB201301626D0 (en) * 2013-01-30 2013-03-13 Dignity Sciences Ltd Composition comprising 15-OHEPA and methods of using the same
MA41120A (fr) 2014-12-02 2017-10-10 Afimmune Ltd Compositions comprenant le 15-hepe et méthodes de traitement ou de prévention de la fibrose à l'aide de celles-ci
JP2018520197A (ja) * 2015-07-21 2018-07-26 アフィミューン リミテッド 癌及び神経疾患の治療または予防において使用するための、１５−ｈｅｐｅを含む組成物
KR20180094516A (ko) 2015-12-18 2018-08-23 애피뮨 리미티드 15-hepe를 포함하는 조성물 및 이를 사용하는 방법

Also Published As

Publication number Publication date
MX2015009803A (es) 2015-10-29
ZA201505018B (en) 2017-01-25
KR20220119524A (ko) 2022-08-29
KR20250105691A (ko) 2025-07-08
CN111214464A (zh) 2020-06-02
KR102434817B1 (ko) 2022-08-19
EP2762143A1 (en) 2014-08-06
US20210244697A1 (en) 2021-08-12
IL239893A (en) 2017-04-30
KR20240011872A (ko) 2024-01-26
US20210228524A1 (en) 2021-07-29
US20200069626A1 (en) 2020-03-05
IL239893A0 (en) 2015-08-31
ES2564025T3 (es) 2016-03-17
JP2016511753A (ja) 2016-04-21
CA2897343A1 (en) 2014-08-07
GB201301626D0 (en) 2013-03-13
SI2762143T1 (sl) 2016-04-29
RU2015136849A (ru) 2017-03-06
MX364646B (es) 2019-05-03
MX2019005082A (es) 2019-08-12
JP6363104B2 (ja) 2018-07-25
RS54584B1 (sr) 2016-08-31
CA2897343C (en) 2021-03-16
AU2018206685A1 (en) 2018-08-02
US10813903B2 (en) 2020-10-27
BR112015018270A2 (pt) 2017-07-18
EP2762143B1 (en) 2015-12-02
SMT201600069B (it) 2016-04-29
US20150224076A1 (en) 2015-08-13
KR20150112995A (ko) 2015-10-07
AU2014211628B2 (en) 2018-04-19
PL2762143T3 (pl) 2016-06-30
IL251639A0 (en) 2017-06-29
CY1117209T1 (el) 2017-04-05
SG10201806854XA (en) 2018-09-27
AU2014211628A1 (en) 2015-07-30
DK2762143T3 (en) 2016-03-07
EP3058943B1 (en) 2019-09-25
ZA201605125B (en) 2018-06-27
US20220347147A1 (en) 2022-11-03
HUE026901T2 (en) 2016-07-28
KR20210088733A (ko) 2021-07-14
WO2014118097A1 (en) 2014-08-07
KR102274963B1 (ko) 2021-07-08
PT2762143E (pt) 2016-03-28
ES2759448T3 (es) 2020-05-11
IL265876A (en) 2019-06-30
RU2671208C2 (ru) 2018-10-30
PH12015501582A1 (en) 2015-10-05
SG11201505457PA (en) 2015-08-28
CN105120872A (zh) 2015-12-02
US20250186384A1 (en) 2025-06-12
HK1200351A1 (en) 2015-08-07
EP3058943A1 (en) 2016-08-24
JP2018172409A (ja) 2018-11-08
HRP20160203T1 (hr) 2016-03-25
CN105120872B (zh) 2020-01-10
PH12015501582B1 (en) 2019-10-25
RU2018136872A (ru) 2018-11-27
KR102514913B1 (ko) 2023-03-27
KR20230047201A (ko) 2023-04-06

Similar Documents

Publication Publication Date Title
NZ709803A (en) Compositions comprising 15-ohepa and methods of using the same
GEP201706663B (en) Novel composition for nonalcoholic fatty liver disease (nafld
PH12017501956A1 (en) Compositions of obeticholic acid and methods of use
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2016002544A (es) Compuestos utiles como inmunomoduladores.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
MX360979B (es) Composiciones de galacto-ramnogalacturonato para el tratamiento de la esteatohepatitis no alcohólica y de la enfermedad del higado graso no alcohólico.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
WO2016019134A8 (en) Flagellin-based agents and uses including effective vaccination
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EP4614148A3 (en) Synergistic enhancement of the delivery of nucleic acids via blended formulations
HK1216175A1 (zh) 治療性化合物和組合物
MY186547A (en) 4?-fluoro-2?-methyl substituted nucleoside derivatives
EA201890767A1 (ru) C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
PH12018500852B1 (en) Novel cryptophycin compounds and conjugates, their preparation and their therapeutic use
PH12016502050A1 (en) Homovanillinic acid ester, in particular, for creating a hot and/or pungent taste sensation
PH12019501362A1 (en) Polymorphs
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2015008877A (es) Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos.
PH12016501519B1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018014129A (es) Composiciones farmaceuticas de oligomero de morfolino fosforodiamidato.
MX2019002579A (es) Composiciones y metodos de uso de depuradores de gamma-cetoaldehido para tratar, evitar o mejorar la enfermedad del higado graso no alcoholico (nafld), nash, ald o condiciones relacionadas al higado.
PH12015502717A1 (en) Anti-fibrogenic compounds, methods and uses thereof
MX2017013772A (es) Conjugados mezclados de disulfuro de compuestos de tienopiridina y usos de los mismos.

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: AFIMMUNE LIMITED, IE

Effective date: 20170616

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2022 BY CPA GLOBAL

Effective date: 20201211

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 24 JAN 2023 BY CPA GLOBAL

Effective date: 20211210

LAPS Patent lapsed